Important resolutions of the Company's 2022
Annual Shareholders' Meeting
Date of events
2022/05/27
To which item it meets
paragraph 18
Statement
1.Date of the shareholders' meeting:2022/05/27
2.Important resolutions I.Profit distribution/deficit compensation:
Acknowledgment of the proposal for distribution of 2021 net profits
3.Important resolutions II.Amendments of the company charter:
Acceptance of the amendments to the Company's "Articles of Incorporation"
4.Important resolutions III.Business report and financial statements:
Acknowledgment of the 2021 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
To elect new 9 Directors (including 3 Independent Directors). The list of
Directors elected:
Independent Directors: Chien-Huang Lin, Ming-Daw Chang, Chih-Li Wang
Directors: Ming-Feng Hou
Directors:
Legal Representative of TTY Biopharm Co., Ltd.: Ted Tu, Wen-Hung Hsu,
Rui-Wen Wu
Legal Representative of National Development Fund, Executive Yuan:
Ming-Shiang Wu, Yi-Hui Lin
6.Important resolutions V.Other matters:
Acceptance of the proposal for releasing the prohibition on Directors or
their representatives from participation in competitive business
7.Any other matters that need to be specified:
(1) Acceptance of the amendments to the Company's "Operational Procedures
of Loaning Funds to Others"
(2) Acceptance of the amendments to the Company's " Operational Procedures
for Acquisition & Disposal of Asset"
(3) Acceptance of the amendments to the Company's "Procedures for Election
of Directors"
(4) Acceptance of the issuance of restricted stock awards
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 27 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2022 10:41:57 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,